Intervention group (n = 30) | Control group (n = 30) | |||||
---|---|---|---|---|---|---|
HR | CI 95 % | P-value | HR | CI 95 % | P-value | |
Pathological fracture | 1.288 | 0.371–4.467 | 0.690 | 0.833 | 0.343–2.020 | 0.686 |
KPS | 0.527 | 0.216–1.289 | 0.161 | 0.872 | 0.372–2.043 | 0.752 |
Localization | 0.588 | 0.209–1.655 | 0.315 | 1.166 | 0.504–2.694 | 0.720 |
Number of metastases | 0.602 | 0.200–1.812 | 0.366 | 1.052 | 0.469–2.360 | 0.902 |
Breast cancer | 0.230 | 0.028–1.923 | 0.175 | 0.103 | 0.024–0.442 | 0.002 |
NSCLC | 2.442 | 0.834–7.145 | 0.103 | 0.968 | 0.346–2.712 | 0.951 |
Prostate cancer | 0.950 | 0.237–3.804 | 0.942 | 0.160 | 0.050–0.511 | 0.002 |
Cerebral metastases | 1.529 | 0.409–5.716 | 0.528 | 3.211 | 1.063 − 9.695 | 0.038 |